- Share - [](https://www.facebook.com/sharer.php?u=https://about.ebsco.com/markdownify/node/88228) - []() - []() - []() # Expert Opinion in EBM: Adjunctive Imaging for Breast Cancer Screening EBM Focus introduces “Focus on Expert Opinion” to highlight what experts think are the most important evidence-based developments in their field of expertise. This week’s expert is Dr. Adena Scheer, with a Q&A on breast cancer screening. ![Image of a female nurse looking at a chart while consulting with a patient](https://assets.ebsco.com/asset/f76d431e-3c24-4e08-9bed-98ab20c4b103/woman-patient-doctor-chart-blog-image-780-jpg.jpg) [Dan Randall, MD, MPH, FACP](/health-notes/bio/dan-randall-md-mph-facp) 23 October 2024 Dr. Adena Scheer is an Assistant Professor of Surgery at the University of Toronto and researcher specializing in breast cancer as well as the topic editor for our DynaMedex topic: [Breast Cancer Screening](https://www.dynamedex.com/prevention/breast-cancer-screening). For Breast Cancer Awareness Month, we asked Dr. Scheer several questions: 1. **What do you consider the most important piece of evidence or guideline related to breast cancer in the past year?** [The United States Preventive Services Task Force (USPSTF) Recommendation on Breast Cancer Screening](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening), released April 2024. *Editor’s note:* The USPSTF gives a “B” grade of recommendation for screening for breast cancer every two years between the ages of 40 and 74, but an “I” recommendation (for insufficient evidence) for adjunctive testing for patients with dense breasts, such as MRI, ultrasound, or contrast enhanced mammography. Supporting evidence for these recommendations can be found [here](https://pubmed.ncbi.nlm.nih.gov/38687490/). 2. **What’s your clinical “take” on this evidence or guideline? Do you agree or disagree with the conclusions/recommendations? Why?** It’s interesting that the USPSTF took the stance that there was insufficient evidence to recommend for or against adjunctive testing based on breast density given that the Ontario guidelines took exactly the opposite. As of Spring 2024, [Health Quality Ontario](https://hqontario.ca/evidence-to-improve-care/health-technology-assessment/reviews-and-recommendations/supplemental-screening-as-an-adjunct-to-mammography-for-breast-cancer-screening-in-people-with-dense-breasts) recommends supplemental screening for dense breasts based on their health technology assessment/systematic review. The DENSE Trial in particular (found [here](https://pubmed.ncbi.nlm.nih.gov/31774954/), with second-round results found [here](https://pubmed.ncbi.nlm.nih.gov/33724062/)) showed a reduction in interval cancer detection with supplemental MRI. In Ontario, Canada, we now recommend adjunctive testing. 3. **How will this publication influence practice and patient care? Will it have a large or small impact on your daily decision-making?** This will have a large impact on decision-making, specifically for practitioners in the United States. As of September 10, 2024, in the United States, letters will be required to tell a patient their breasts are “dense” or “not dense,” that dense tissue makes it harder to find cancers on a mammogram, and that it increases the risk of developing cancer. Patients with dense breasts will also be told that other imaging tests in addition to a mammogram may help find cancers. In my practice, I recommend bilateral screening ultrasound yearly in conjunction with a mammogram for patients with dense breasts without a family history. For patients with dense breasts and a family history of breast cancer, I offer yearly mammograms and an MRI every other year. For more information, see the topic [Breast Cancer Screening](https://www.dynamedex.com/prevention/breast-cancer-screening) in DynaMedex. [ Sign up for EBM Focus ](https://more.ebsco.com/EBM-Focus-Newsletter-Signup.html) Category: [Clinical Practice Perspectives ](/blogs/health-notes/category/clinical-practice-perspectives) Tags: [EBMFocus](/blogs/health-notes/tag/ebmfocus) [Evidence–based medicine](/blogs/health-notes/tag/evidence–based-medicine) - Share - [](https://www.facebook.com/sharer.php?u=https://about.ebsco.com/markdownify/node/88228) - []() - []() - []() ## Related Posts [ ![female nurse educating two female patients blog image ](/sites/default/files/acquiadam-assets/female-nurse-educating-two-female-patients-blog-image-780.jpg) ](/blogs/health-notes/2507504/ebm-focus-when-to-start-breast-cancer-screening-devil-in-details) [EBM Focus: When to Begin Breast Cancer Screening; The Devil is in the Details](/blogs/health-notes/2507504/ebm-focus-when-to-start-breast-cancer-screening-devil-in-details) 8 June 2023 [ ![ACP Guidance Statement Blog Image ](/sites/default/files/acquiadam-assets/ACP%20Guidance%20Statement-Blog-Image-780.jpg) ](/blogs/health-notes/acp-guidance-statement-highlights-harms-screening-mammography-among-average-risk) [ACP Guidance Statement Highlights Harms of Screening Mammography Among Average-risk Women Aged 40-49](/blogs/health-notes/acp-guidance-statement-highlights-harms-screening-mammography-among-average-risk) 7 May 2019 [ ![doctor talking to patient clipboard blog image template ](/sites/default/files/acquiadam-assets/doctor-talking-to-patient-clipboard-blog-image-template-780.jpg) ](/blogs/health-notes/2022490/ebm-focus-surviving-overdiagnosis-breast-cancer) [EBM Focus: Surviving Overdiagnosis of Breast Cancer](/blogs/health-notes/2022490/ebm-focus-surviving-overdiagnosis-breast-cancer) 27 April 2022